This retrospective cohort study (2013–2025, n=77) evaluated multisite complete remission (mCR) and site-specific treatment response patterns in patients with immunopathology-confirmed mucous membrane pemphigoid (MMP) involving ≥2 anatomic sites, with ≥12 months of follow-up.
Only 35 of 77 patients (45%) achieved mCR, taking a median of 32 months; while 64 (83%) reached complete remission at ≥1 site, persistent oral and ocular disease most often blocked global control. Relapses after site-level CR occurred in 44%, most commonly at oral (64%) and ocular (50%) mucosa. Rituximab-based regimens and JAK inhibitor therapy showed high improvement rates; serious adverse events were most frequent with cyclophosphamide monotherapy and JAK inhibitors.
Single tertiary referral center limits generalizability to less complex or community-based MMP populations. Retrospective design introduces selection and documentation bias. No head-to-head controlled comparisons between treatment regimens were performed.
Clinicians should not equate site-level remission with disease control in multisite MMP—nearly half of patients never achieve simultaneous remission across all sites, and relapses are common especially at oral and ocular mucosa. Standardized multisite remission endpoints should be incorporated into future trials and clinical monitoring plans.